By Iain Gilbert
Date: Tuesday 15 Sep 2026
(Sharecast News) - Analysts at Berenberg upgraded drugmaker GSK from 'hold' to 'buy' on Tuesday and lifted their target price on the stock from £20 to £22, saying recent business‑development activity and pipeline momentum had strengthened the firm's long‑term growth outlook and left its valuation discount looking excessive.
| Total Voting Rights | 01-Oct-2026 | 15:00 | RNS |
| Director/PDMR Shareholding | 24-Sep-2026 | 15:30 | RNS |
| Director/PDMR Shareholding | 22-Sep-2026 | 15:30 | RNS |
| GSK to acquire T cell-engager for multiple myeloma | 15-Sep-2026 | 07:00 | RNS |
| Jideytro positive data for ROS1-positive NSCLC | 14-Sep-2026 | 07:00 | RNS |
| GSK invests £400m to relocate research headquart... | 28-Jul-2026 | Times |
| GSK to buy US cancer treatment firm Nuvalent for... | 09-Jun-2026 | Guardian |
| GSK signs £45m deal with UCL offshoot for liver ... | 08-Jun-2026 | Times |
| Strong vaccine sales deliver an early boost for ... | 29-Apr-2026 | Times |
| GlaxoSmithKline scraps sale of old drugs | 05-Dec-2014 | Telegraph |
| Questor :GlaxoSmithKline | 16-Apr-2014 | Telegraph |
| Questor:GlaxoSmithKline | 06-Oct-2011 | Telegraph |
| Questor:GlaxoSmithKline | 11-Aug-2011 | Telegraph |
| Questor tip: GlaxoSmithKline | 28-Jul-2011 | Telegraph |
| Investment Column: GlaxoSmithKline | 27-Jul-2011 | The Independent |
| Currency | UK Pounds |
| Share Price | 1,795.00p |
| Change Today | -37.00p |
| % Change | -2.02 % |
| 52 Week High | 2,208.00 |
| 52 Week Low | 1,614.50 |
| Volume | 8,422,483 |
| Shares Issued | 4,045.43m |
| Market Cap | £72,616m |
| Beta | 0.00 |
| RiskGrade | 129 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| Latest | Previous | |
|---|---|---|
| Q2 | Q1 | |
| Ex-Div | 13-Aug-26 | 14-May-26 |
| Paid | 08-Oct-26 | 09-Jul-26 |
| Amount | 17.00p | 17.00p |
| Time | Volume / Share Price |
| 16:39 | 209 @ 1,795.00p |
| 16:39 | 233 @ 1,795.00p |
| 16:39 | 502 @ 1,795.00p |
| 16:39 | 265 @ 1,795.00p |
| 16:37 | 105 @ 1,795.00p |
You are here: research